Translational research of anti-angiogenesis in cancer therapy

Several common cancer drugs based on antiangiogenesis have become key components in the treatment of patients with different types of cancer. While antiangiogenic drugs in combination with chemotherapy significantly improve patient survival, the clinical benefits of antiangiogenic therapy alone remain modest. There are a number of still unresolved clinically related fundamental questions. Why does only combination therapy produce positive effects in patients? Why do patients become resistant to antiangiogenic therapy? How can we optimize existing treatments to maximize clinical benefits? Which biomarkers predict clinical benefit? In this research project, we seek to understand the basic mechanisms of antiangiogenic cancer therapy and translate our preclinical findings into clinical use to improve antiangiogenic cancer treatment. We will use different preclinical models to approach these clinically relevant questions. We also study the role of angiogenesis in cancer metastasis. In particular, we are interested in studying changes in vascular structures that facilitate tumor spread, invasion and metastasis. We will continue to study lymphangiogenesis, which is important as many tumors spread via the lymphatic system. Overall, our research program is translational in nature and the results generated by our research will benefit millions of cancer patients.